GlassScriptPhysician profile
James H Hinton
NPI 1669407425
$2,931.68
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $495 · 2021: $475 · 2022: $428 · 2023: $431 · 2024: $13.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $335.59 | 2019-2022 | |
| Glaxosmithkline, LLC. | $326.91 | 2019-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $325.67 | 2020-2021 | |
| Amarin Pharma, INC. | $311.34 | 2019-2022 | |
| Pfizer INC. | $231.21 | 2019-2021 | |
| Novo Nordisk INC | $178.13 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $154.59 | 2019-2023 | Spravato |
| Abbvie INC. | $121.58 | 2021-2024 | |
| Abbott Laboratories | $94.23 | 2021-2023 | Freestyle Libre 2 |
| Amgen INC. | $92.33 | 2019-2020 | |
| Genentech USA, INC. | $88.93 | 2019-2021 | |
| Exact Sciences Corporation | $78.22 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $72.06 | 2022 | |
| Merck Sharp & Dohme LLC | $62.37 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $51.49 | 2022-2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $43.31 | 2020-2022 | |
| Allergan, INC. | $41.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $40.78 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $40.67 | 2022-2023 | Keveyis |
| Boston Scientific Corporation | $39.15 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $29.61 | 2019 | |
| Hologic Sales and Service, LLC | $19.73 | 2023 | Aptima |
| Teva Pharmaceuticals USA, INC. | $19.48 | 2019 | |
| Medtronic, INC. | $19.24 | 2022 | |
| Wright Medical Technology, INC. | $17.21 | 2019 | |
| Antares Pharma, INC. | $16.65 | 2019 | |
| Esperion Therapeutics, INC. | $16.15 | 2021 | |
| Sanofi Pasteur INC. | $16.14 | 2020 | |
| Insulet Corporation | $14.24 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hinton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.